Martin Vogelbaum

Martin Vogelbaum is a co-founder of Ajax and also serves on the company’s board of directors. He has more than 27 years of investment experience in the life sciences having been involved with companies at all stages of development, including co-founding several biotech start-ups. He is Managing Partner of Inning One Ventures, an early-stage life sciences venture capital firm, and a founding investor of Ajax. Previously, Mr. Vogelbaum served as Corporate Vice President, Business Development at Celgene Corporation. Prior to joining Celgene, Mr. Vogelbaum served as a partner of Rho Ventures where he focused on investments in biopharmaceuticals and medical devices. He serves or has served on the Board of Directors of multiple private and public life sciences companies including Cara Therapeutics (NASDAQ: CARA), Gloucester Pharmaceuticals (acquired by Celgene), Mersana (NASDAQ: MRSN), SARcode (acquired by Shire) and AqueSys (acquired by Allergan). Prior to his venture capital career, he was a research associate in the bone marrow transplantation unit at Memorial Sloan Kettering Cancer Center. He currently serves on the Healthcare Advisory Board for the Partnership Fund for New York City as well as the External Advisory Board for the Office of Therapeutic Alliances at NYU Langone Health. Mr. Vogelbaum received his A.B. in biology and history from Columbia University.